Cancer Immunotherapy: Imaging Assessment of Novel Treatment Response Patterns and Immune-related Adverse Events

New research, clinical trial outcomes, etc.
Post Reply
D.ap
Senior Member
Posts: 4137
Joined: Fri Jan 18, 2013 11:19 am

Cancer Immunotherapy: Imaging Assessment of Novel Treatment Response Patterns and Immune-related Adverse Events

Post by D.ap »

Cancer Immunotherapy: Imaging Assessment of Novel Treatment Response Patterns and Immune-related Adverse Events

"The important concept of cancer immunotherapy, an emerging new treatment modality for cancer, is introduced, and novel response patterns and treatment complications associated with immunotherapy are illustrated to help radiologists accurately interpret post-immunotherapy imaging findings."




http://pubs.rsna.org/doi/full/10.1148/rg.352140121
Debbie
Olga
Admin
Posts: 2349
Joined: Mon Jun 26, 2006 11:46 pm
Location: Vancouver, Canada

Re: Cancer Immunotherapy: Imaging Assessment of Novel Treatment Response Patterns and Immune-related Adverse Events

Post by Olga »

It is a very important article, Debbie.
The one to discuss with the radiologist and with the oncologist if you start one of the newer drugs like TKI, IFN, immunotherapies like vaccines or Immune checkpoint inhibitors (ICI) like Keytruda or Opdivo. First or even few initial scans after the start of these drugs should not be considered as definitive to see if the drug is working as the response itself can create the appearance of the false progression on the initial scans.

Cancer Immunotherapy: Imaging Assessment of Novel Treatment Response Patterns and Immune-related Adverse Events
http://pubs.rsna.org/doi/full/10.1148/rg.352140121
It is avail. in fill text and all people on the novel/non-traditional chemotherapy drugs should read it.
They say (I copy from there):
"Early clinical experience with recombinant cytokines, cancer vaccines, and immunomodulatory monoclonal antibodies has demonstrated a delayed response to treatment compared with that of cytotoxic chemotherapy, clinically significant disease stability, and transient enlargement of tumors or the appearance of new tumors followed by tumor shrinkage or long-term stability of tumor size (4)."
Olga
Post Reply

Return to “Medical Publications”